【レポートの概要（一部）】
1. Report Overview
1.1 Global Next-Generation Antibody Therapies Market Overview
1.2 Global Next-Generation Antibody Therapies Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Introduction to Next-Generation Antibody Therapies
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 Antibodies: An Overview
2.2.1 Monoclonal versus Polyclonal Antibodies
2.2.2 A Brief History of Antibody Drug Development
2.2.3 The Antibody Manufacturing Process
2.2.4 Trends in Antibody Development
2.3 Defining Next-Generation Antibodies
2.3.1 Classification of Next-Generation Antibody Therapies
2.3.2 The Need for Next-Generation Technologies
2.4 Development Trends for Next-Generation Antibodies
2.5 Phases of Clinical Trials
2.6 Scope of this Report
2.7 Currency Exchange Rates in This Report
3. Next-Generation Antibody Therapies: World Market 2015-2025
3.1 The World Next-Generation Antibody Therapies Market in 2014
3.1.1 Next-Generation Antibody Therapies Market Segmentation, 2014
3.1.2 Leading Next-Generation Antibody Therapies Products
3.2 World Next-Generation Antibody Therapies Market: Sales Forecast 2015-2025
3.3 How Will Segmental Market Shares Change to 2025?
3.4 World Next-Generation Antibody Therapies Market: Drivers and Restraints 2015-2025
4. Leading Regional Markets 2015-2025
4.1 Regional Breakdown of the World Next-Generation Antibody Therapies Market
4.2 World Next-Generation Antibody Therapies Market: Regional Forecast 2015-2025
4.3 How Will Regional Market Shares Change to 2025?
4.4 US Next-Generation Antibody Therapies Market 2015-2025
4.5 EU5 Next-Generation Antibody Therapies Market 2015-2025
4.6 Asia-Pacific Next-Generation Antibody Therapies Market 2015-2025
4.7 Latin American Next-Generation Antibody Therapies Market 2015-2025
4.8 The Next-Generation Antibody Therapies Market in the Rest of the World 2015-2025
5. Antibody-Drug Conjugates: Market Forecast and Pipeline 2015-2025
5.1 Antibody-Drug Conjugates: Market Overview, 2015
5.2 Leading ADCs in 2015
5.3 Antibody-Drug Conjugates: Market Forecast 2015-2025
5.4 The Antibody-Drug Conjugates Market: Drivers and Restraints 2015-2025
5.4.1 Competition for Leading Drugs Will Restrain Growth in 2015-2025
5.4.2 Manufacturing ADCs Forms a Challenge
5.5 Adcetris (brentuximab vedotin, Seattle Genetics/Takeda)
5.5.1 Adcetris: Sales Forecast 2015-2025
5.5.2 Adcetris Meets Primary Endpoint in AETHERA Trial
5.5.3 Expanding Adcetris Indications for Future Revenue Growth
5.6 Kadcyla (trastuzumab emtansine, Roche)
5.6.1 Kadcyla: Sales Forecast 2015-2025
5.6.2 Phase 3 Results for Kadcyla/Perjeta Combination Disappoint
5.7 Mylotarg (gemtuzumab ozogamicin, Pfizer)
5.7.1 Mylotarg to be Relaunched?
5.8 Antibody-Drug Conjugate Platforms
5.8.1 Limited Market Opportunity for Radioconjugation
5.8.2 Seattle Genetics’ Platform Accounts for Over 50% of the Pipeline
5.8.3 ImmunoGen: TAP Technology
5.8.4 Immunomedics: Lower Potency Cytotoxics for Extended Use
5.8.5 Preclinical Platforms for ADC Development
5.9 ADCs Are Attracting High-Value Deals
5.10 Antibody-Drug Conjugates: Pipeline Analysis 2015-2025
5.10.1 The Longest Pipeline in the Next-Generation Antibodies Market
5.10.2 Cancer Is the Only Target for Current Clinical-Stage ADCs
5.11 Antibody-Drug Conjugates: Phase 3 Pipeline
5.11.1 CMC544 (inotuzumab ozogamicin, Pfizer)
5.11.2 Roche Attempts to Expand Kadcyla’s Breast Cancer Indication
5.11.2.1 RG7596 (polatuzumab vedotin) for NHL and DLBCL
5.11.2.2 RG7599/DNIB0600A (anti-NaPi2b) for Ovarian Cancer
5.11.2.3 RG7450/DSTP3086S (anti-STEAP1) for Prostate Cancer
5.12 Antibody-Drug Conjugates: Phase 2 Pipeline
5.12.1 ABT-414 (anti-EGFR, AbbVie/Seattle Genetics)
5.12.2 BT-062 (indatuximab ravtansine; anti-CD138, Biotest)
5.12.3 CDX-011 (glembatumumab vedotin; anti-glycoprotein NMB, Celldex Therapeutics/Seattle Genetics)
5.12.4 Immunomedics’ IMMU-130 (labetuzumab-SN-38; anti-CEA/CD66e) and IMMU-132 (anti-TROP-2)
5.12.5 MLN0264 (anti-GCC, Millennium Pharmaceuticals/Seattle Genetics)
5.12.6 MM-302 (anti-HER2, Merrimack Pharmaceuticals)
5.12.7 PSMA ADC (anti-PSMA, Progenics Pharmaceuticals/Seattle Genetics)
5.12.8 SAR3419 (coltuximab ravtansine) (anti-CD19, Sanofi)
5.12.9 Seattle Genetics’ Phase 1 and Phase 2 ADCs
5.12.9.1 SGN-CD19A (anti-CD19) for DLBCL and ALL
5.12.9.2 SGN-LIV1A (anti-LIV-1) for Relapsed Breast Cancer
5.12.9.3 SGN-CD33A: Using a New Cytotoxin and Linker Technology
5.12.9.4 SGN-CD70A (anti-CD70, Seattle Genetics)
5.13 Antibody-Drug Conjugates: Phase 1 Pipeline
5.13.1 Astellas Pharma: Partnered with Seattle Genetics for Phase 1 ADCs
5.13.2 Amgen’s AMG 595 (anti-EGFRv3) and AMG 172 (anti-CD27L)
5.13.3 Bayer’s Pipeline ADCs
5.13.3.1 Anetumab ravtansine (BAY 94-9343) (anti-mesothelin, Bayer)
5.13.3.2 C4.4a-ADC/BAY1129980 (anti-C4.4a, Bayer/Seattle Genetics)
5.13.3.3 FGFR2-ADC (anti-FGFR2, Bayer)
5.13.4 GSK2857916 (anti-BCMA, GSK/Seattle Genetics)
5.13.5 HuMax-TF-ADC (anti-TF, Genmab/Seattle Genetics)
5.13.6 ImmunoGen’s IMGN529 (anti-CD37), IMGN853 (anti-Folate receptor α) and IMGN289 (anti-EGFR)
5.13.7 LOP628 (anti-cKit, Novartis)
5.13.8 PF-06263507 (anti-5T4, Pfizer/Seattle Genetics)
5.13.9 Sanofi’s SAR408701 (anti-CEACAM5) and SAR566658 (anti-CA6)
5.13.10 SYD985 (trastuzumab duocarmycin; anti-HER2, Synthon)
5.14 Antibody-Drug Conjugates: Preclinical Pipeline
5.15 Future Developments in ADC Technology
5.15.1 Site-Specific Linkage for Improved Safety Profiles
6. Engineered Antibodies: Market Forecast and Pipeline 2015-2025
6.1 Engineered Antibodies: Market Overview, 2015
6.2 Leading Engineered Antibodies in 2015
6.3 Engineered Antibodies: Market Forecast 2015-2025
6.4 The Engineered Antibodies Market: Drivers and Restraints 2015-2025
6.5 Poteligeo (mogamulizumab, Kyowa Hakko Kirin)
6.5.1 Poteligeo: Sales Forecast 2015-2025
6.6 Gazyva/Gazyvaro (obinutuzumab, Roche)
6.6.1 Gazyva as a Challenger in the anti-CD20 Market
6.6.2 Competition beyond Rituxan and Biosimilars
6.6.3 Gazyva: Sales Forecast 2015-2025
6.7 Engineered Antibodies Platforms
6.7.1 Roche Glycart: GlucoMAb – Glycosylation for Improved ADCC
6.7.2 Kyowa Hakko Kirin: Potelligent – Enhancing ADCC
6.7.3 Glycotope: GlycoExpress
6.7.4 MacroGenics: Fc Optimization
6.7.5 Xencor: XmAb – Modifying Amino Acids in the Fc Domain
6.7.6 Other Platforms for Increased Potency
6.8 Engineered Antibodies: Pipeline Analysis 2015-2025
6.9 Engineered Antibodies: Phase 3 Pipeline
6.9.1 Benralizumab (MedImmune/Kyowa Hakko Kirin)
6.9.2 Elotuzumab (anti-SLAMF7, Bristol-Myers Squibb/AbbVie)
6.9.3 MEDI4736 (anti-PDL1, AstraZeneca)
6.9.4 RG7446/MPDL3280A (anti-PDL1, Roche)
6.9.5 Ublituximab (anti-CD20, TG Therapeutics)
6.10 Engineered Antibodies: Phase 2 Pipeline
6.10.1 Glycotope’s CetuGEX (anti-EGFR), PankoMab-GEX (anti-TA-MUC1) and TrasGEX (anti-HER2)
6.10.2 Margetuximab (anti-HER2, MacroGenics)
6.10.3 MEDI-551 (anti-CD19, AstraZeneca)
6.10.4 MOR-208 (XmAb5574) (anti-CD19, MorphoSys/Xencor)
6.10.5 Teplizumab (anti-CD3, MacroGenics)
6.10.6 BIW-8962 (anti-GM2, Kyowa Hakko Kirin)
6.10.7 XmAb5871 (anti-CD19, Xencor)
6.11 Engineered Antibodies: Phase 1 Pipeline
6.11.1 Ocaratuzumab (anti-CD20, Mentrik Biotech)
6.11.2 RG7116 (anti-HER3, Roche)
6.11.3 MGA271 (MacroGenics/Servier)
7. Bispecific Antibodies: Market Forecast and Pipeline 2015-2025
7.1 Bispecific Antibodies: Market Overview, 2015
7.2 Bispecific Antibodies: Market Forecast 2015-2025
7.3 The Bispecific Antibodies Market: Drivers and Restraints 2015-2025
7.3.1 Manufacturing Bispecific Antibodies: Maintaining Stability and Purification
7.4 Removab (catumaxomab, Neopharm)
7.4.1 Removab: Sales Forecast 2015-2025
7.5 Blincyto (blinatumomab, Amgen)
7.5.1 Blincyto: Sales Forecast 2015-2025
7.6 Bispecific Antibodies Platforms
7.6.1 BiTE Platform: The Current Market Leader
7.6.2 MacroGenics’ DART Platform Holds Promise
7.6.3 TriomAbs (TRION Pharma): Limited Market Impact 2014-2024
7.6.4 Other Bispecific Antibody Platforms
7.6.4.1 DuoBodies (Genmab)
7.6.4.2 ImmTAC (Immunocore)
7.7 Bispecific Antibodies: Pipeline Analysis 2015-2025
7.8 Bispecific Antibodies: Phase 2 and Phase 3 Pipeline
7.8.1 ABT-122 (anti-TNF and IL-17A) and ABT-981 (anti-IL-1α and IL-1β, AbbVie)
7.8.2 AFM13 (anti-CD30 and CD16A, Affimed Therapeutics)
7.8.3 MM-111 (anti-ErbB2 and ErbB3, Merrimack Pharmaceuticals)
7.8.4 MM-141 (anti-IGF-1R and ErbB3, Merrimack Pharmaceuticals)
7.8.5 SAR156597 (anti-IL-4 and IL-13, Sanofi)
7.8.6 Vanucizumab (RG7221; anti-Ang2 and VEGF-A, Roche)
7.9 Bispecific Antibodies: Phase 1 and Phase 1/2 Pipeline
7.9.1 COVA322 (anti-TNF and IL-17A, Johnson & Johnson)
7.9.2 IMCgp100 (anti-HLA-A2 and CD3, Immunocore)
7.9.3 Lymphomun (anti-CD20 and CD3, Trion Pharma/Fresenius Biotech)
7.9.4 MCLA-128 (anti-HER2 and HER3, Merus)
7.9.5 Rexomun (ertumaxomab) (anti-HER2 and CD3, Neopharm)
7.9.6 TF2 (anti-CEACAM5, Immunomedics)
7.9.7 AMG 211 (anti-CEA and CD3, Amgen/MedImmune)
7.9.8 BAY2010112 (MT112) (anti-PSMA and CD3, Bayer)
7.10 Bispecific Antibodies: Preclinical Pipeline
8. Antibody Fragments and Antibody-Like Proteins (ALPs): Market Forecast and Pipeline 2015-2025
8.1 Antibody Fragments and ALPs: Market Overview, 2015
8.2 Antibody Fragments and ALPs: Market Forecast 2015-2025
8.3 The Antibody Fragments and ALPs Market: Drivers and Restraints 2015-2025
8.4 Kalbitor (ecallantide, Dyax)
8.4.1 Kalbitor: Sales Forecast 2015-2025
8.5 Antibody Fragments and ALPs Platforms
8.5.1 Single-chain Variable Fragment Platforms
8.5.1.1 ESBATech and Delenex Therapeutics: Two Approaches Using the Same Platform
8.5.1.2 Nanobodies: The Smallest Antibody Fragment
8.5.1.3 Ablynx’s Nanobody Platform Has Created Many Clinical Candidates
8.5.1.4 Domain Antibodies: GSK and Crescendo Biologics
8.5.2 Non-Antibody Protein Scaffolds: Antibody-Like Proteins
8.5.2.1 DARPins: One-Tenth the Size of Antibodies
8.5.2.2 Anticalins (Pieris): Tested in Clinical Trials
8.5.2.3 Affibodies (Affibody)
8.5.2.4 Fynomers (Covagen/Johnson & Johnson)
8.5.2.5 Affilins (Scil Proteins): Three Products in Pre-Clinical Development?
8.5.2.6 Adnectins (Bristol-Myers Squibb)
8.5.2.7 AdAlta: i-bodies
8.5.3 Which Platform Will Lead the Market 2014-2024?
8.6 Antibody Fragments and ALPs: Pipeline Analysis 2015-2025
8.7 Antibody Fragments and ALPs: Phase 2 Pipeline
8.7.1 Ablynx Leads the Pipeline with Six Clinical Projects
8.7.1.1 Caplacizumab (anti-vWF)
8.7.1.2 ALX-0061 (anti-IL-6R, Ablynx/AbbVie)
8.7.1.3 Ozoralizumab (anti-TNFα)
8.7.1.4 ALX-0171 (anti-respiratory syncytial virus)
8.7.1.5 ALX-0141 (anti-RANKL, Ablynx/Eddingpharm)
8.7.1.6 ALX-0761 (anti-IL-17A and IL-17F, Ablynx/Merck Serono)
8.7.2 Abicipar (anti-VEGF, Allergan/Molecular Partners)
8.7.3 DLX105 (anti-TNF-α, Delenex Therapeutics)
8.7.4 ESBA1008 (anti-VEGF, Novartis)
8.8 Antibody Fragments and ALPs: Phase 1 Pipeline
8.9 Antibody Fragments and ALPs: Preclinical Pipeline
9. Biosimilar Antibodies: Market Forecast 2015-2025
9.1 Biosimilar Antibodies: Market Overview, 2015
9.2 Leading Biosimilar Antibodies in 2015
9.3 Biosimilar Antibodies: Market Forecast 2015-2025
9.4 The Biosimilar Antibodies Market: Drivers and Restraints 2015-2025
9.4.1.1 How Can Developers Ensure Uptake Among Physicians?
9.4.1.2 Automatic Substitution of Biosimilar Antibodies
9.4.1.3 Patent Expiries Will Hit Many Leading Antibodies in this Decade
9.4.1.4 Will Biosimilars Challenge Next-Generation Antibodies in this Decade?
10. Qualitative Analysis of the Next-Generation Antibody Therapies Market 2015-2025
10.1 SWOT Analysis of the Next-Generation Antibody Therapies Market
10.1.1 Strengths
10.1.1.1 Approved Products Indicate a Path to Market Acceptance
10.1.2 Weaknesses
10.1.2.1 Challenges Exist With Current Monoclonal Antibody Therapies
10.1.3 Opportunities
10.1.3.1 Big Pharma Is Investing Heavily in Next-Generation Pipelines
10.1.4 Threats
10.1.4.1 Will Biosimilars Slow Growth in the Next-Generation Antibody Market?
10.2 STEP Analysis of the Next-Generation Antibody Therapies Market
10.2.1 Social Factors: Rising Demand for Cancer Therapies
10.2.1.1 Cancer Incidence Is Rising Rapidly
10.2.1.2 Next-Generation Antibodies for Personalised Medicine
10.2.2 Technological Developments Will Drive Pipeline Growth
10.2.2.1 There Are Many Competing Platforms
10.2.2.2 Manufacturing Challenges Exist for Most Sectors
10.2.2.3 New Analytical Tools for Target Identification and Protein Characterisation
10.2.3 Economic Pressures
10.2.3.1 Next-Generation Antibodies Are High-Cost
10.2.3.2 Outsourced Manufacturing: CMOs Are Expanding Capabilities
10.2.3.3 Next-Generation Launches for Product Lifecycle Management
10.2.4 Political and Regulatory Issues
10.2.4.1 Regulatory Challenges for Biosimilar Antibodies
10.3 Key Targets for Next-Generation Antibody Development 2015-2025
10.3.1 Oncology Is the Lead Indication in All Sectors
10.3.1.1 HER2 and HER3 for Breast Cancer
10.3.1.2 CD19 and CD20 for Lymphoma and Leukaemia
11. Research Interviews
11.1 Interview with Dr. Edwin Moses, CEO, Ablynx, Belgium
11.1.1 The Benefits of Nanobodies over Traditional Antibody Therapies
11.1.2 Manufacturing Nanobodies
11.1.3 Turning Challenges to Advantages
11.1.4 Nanobodies Are Further Developed than Other Antibody Scaffolds
11.1.5 The Commercial Potential for Nanobodies
11.1.6 Next-Generation Antibodies in China and Other Emerging Markets
11.2 Interview with Tim van Hauwermeiren, CEO, ArGEN-X, the Netherlands and Belgium
11.2.1 ArGEN-X’s Development Pipeline
11.2.2 Enhancing the Activity of ARGX-111
11.2.3 ArGEN-X’s SIMPLE Antibody™ Platform
11.2.4 Commercial Prospects for ArGEN-X’s Antibodies
11.2.5 Plans for Growth
11.2.6 Opportunities and Challenges for Next-Generation Antibody Developers
11.2.7 Therapeutic Areas for Manufacturers of Antibody Therapies
11.2.8 Other Trends and Developments in the Market
11.3 Interview with Mersana Therapeutics, Cambridge, Massachusetts, USA
11.3.1 Mersana’s Development Pipeline
11.3.2 Advantages of the Fleximer Platform
11.3.3 Future Plans for Mersana
11.3.4 The Outlook for ADCs in 2015-2025
12. Conclusions
12.1 High Growth Potential in the Next-Generation Antibody Therapies Market in 2015-2025
12.2 The World Next-Generation Antibody Therapies Market in 2014
12.2.1 Current Leading Next-Generation Antibody Therapies Segments
12.2.2 Leading Novel Next-Generation Antibody Therapies
12.2.3 Leading Regional Markets
12.3 World Next-Generation Antibody Therapies Market Forecast 2015-2025
12.4 Next-Generation Antibody Therapies: Late-Stage Pipeline
12.5 The Future of the Next-Generation Antibody Therapies Market?
12.5.1 A Strong Phase 1 and Phase 2 Pipeline
12.5.2 Technology Platforms Will Continue to Attract Big Pharma Interest
12.5.3 Most Developers Continue to Target Cancer
12.5.4 Strategies for Growth in 2015-2025
13. Glossary
【レポート販売概要】
■ タイトル：次世代抗体療法の世界市場：抗体薬物複合体（ADC）、エンジニアード抗体、二重特異性抗体、抗体断片/ALP、バイオシミラー抗体■ 英文：Next-Generation Antibody Therapies Market Forecast 2015-2025 : Opportunities for Leading Companies in ADCs, Engineered Antibodies, ALPs and Biosimilar Antibodies
■ 発行日：2015年5月
■ 調査会社：visiongain
■ 商品コード：VGAIN5052606
■ 調査対象地域：グローバル
- 外科用シーラントおよび接着剤の世界市場分析：タイプ別（天然･生物学的接着剤･シーラント、合成および半合成接着剤）、用途別、地域別、セグメント予測、2014-2025The global surgical sealants and adhesives market is expected to reach a value of USD 4.5 billion by 2025, according to a new report by Grand View Research, Inc. Proper closure of injured tissues post operation is a major step to restore tissue’s structure and function. Postoperative leakages occur in 3% to 15% of cases and are considered as a serious complication. They are responsible for one thi …
- Pressure Relief Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018Pressure Relief Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Summary GlobalData’s new report, “Pressure Relief Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018” provides key market data on the Pressure Relief Devices market in the BRICS countries. The report provides value ($m), volume (units) and average price ($) data fo …
- ナイシンの世界市場Nisin (CAS 1414-45-5) Market Research Report 2014 presents comprehensive data on nisin markets globally and regionally (Europe, Asia, North America etc.) The report includes nisin description, covers its application areas and related patterns. It overviews nisin market, names nisin producers and indicates its suppliers. Besides, the report provides nisin prices in regional markets. In addition to …
- 世界の乳酸及びポリ乳酸市場動向と予測（～2019）Lactic acid-based biodegradable polymers are projected to drive the demand for lactic acid across various industrial applications. The food & beverage segment is the second-largest application for lactic acid and will continue to drive the demand in this market. In this segment, lactic acid is mainly used as an acidulant, pH adjuster, and a preservative. The growth in this segment is projected to …
- 腹水(Ascites)：世界の治験レビュー（2015年上半期版）Ascites Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Ascites Global Clinical Trials Review, H1, 2015" provides data on the Ascites clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ascites. It includes an overview of the trial numbers and their recruitment status as per the site of trial conductio …
- 脊椎インプラントおよび手術機器の世界市場予測（～2021）：胸椎固定装置、腰椎固定装置、頸椎固定装置、脊椎用生物製剤、VCF治療機器、脊髄減圧、非固定装置、脊椎骨刺激器The global spinal implants market is estimated to reach 17.27 Billion by 2021, at a CAGR of 5.3% from 2016 to 2021. A number of factors such as technological advancements in spine surgery devices, increasing aging and obese population along with the rising incidence and prevalence of spinal disorders, and rising demand for minimally invasive spine surgery are propelling the growth of the global sp …
- RhinovirusTesting Market 2014The report presents a detailed analysis of the Rhinovirus diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Rhinovirus definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals - Co …
- くもり止め蓋フィルムの世界市場2019-2023Global Anti-fog Lidding Films Market: About this market Anti-fog lidding films are specialty plastic films that provide modified atmosphere packaging, which helps in the preservation and shelf life extension of perishable food products such as meats, seafood, dairy products, fresh produce, ready-to-eat food items, bakery and confectionary items, and frozen food products. Technavio’s anti-fog liddi …
- 血液培養試験の世界市場分析：製品別（消耗品、機器）、技術別（培養技術）、用途別、方法別、エンドユーザー別、セグメント予測、2014-2025The global blood culture tests market is expected to reach USD 6.6 billion by the year 2025, according to a new report by Grand View Research, Inc. The increasing prevalence of bloodstream infections and infectious diseases is the most significant factor anticipated to propel the market growth during the forecast period. Increasing demand for advanced diagnostic techniques for the diagnosis of inf …
- 世界の運動用フットウェア市場動向（2012-2016）TechNavio's analysts forecast the Global Athletic Footwear market to grow at a CAGR of 1.75 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for comfortable footwear. The Global Athletic Footwear market has also been witnessing the increasing demand for lightweight athletic shoes. However, the increasing availability of counterfe …
- 解剖病理学の世界市場予測：機器（組織処理システム、ミクロトーム）、消耗品（抗体）、組織病理学“High incidence of cancer & other target diseases, availability of reimbursement, and the growing focus on personalized medicine are driving the overall growth of the anatomic pathology market”The anatomic pathology market is projected to reach a value of USD 44.4 billion by 2024 from USD 33.0 billion in 2019, at a CAGR of 6.1% during the forecast period. The growth in this market is attributed to …
- 2014年スペインの分子血液型・分類検査および感染症NAT（核酸増幅検査）市場Complete report $6,100. DataPack (test volumes, sales forecasts, supplier shares) $3,950. This comprehensive report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the Spanish molecular blood banking market during the next five years, and assist industry executives in developing effective business, new product development an …
- 酸化マグネシウム・ナノ粒子の世界市場2010-2025Due to their exceptional chemical, thermal, electrical and optical properties (e.g. high thermal stability and melting point, small dielectric constant, etc), magnesium oxide nanoparticles (MgO-NPs) find application in a variety of industries. MgO-NPs have been incorporated into catalysis, refractory materials, and superconductors. Various MgO structures, such as nanocrystals, nanoparticles, nanoc …
- 圧力容器の世界市場：ボイラー、原子炉、セパレーターThe pressure vessel market is expected to reach USD 184.87 Billion by 2021, at a CAGR of 5.38% from 2016 to 2021. The growth of this market is attributed to huge electricity demand and industrialization in different regions. Investments for renewable power generation in Asia-Pacific and North American countries have been planned to meet the rising power demand, which in turn are going to boost the …
- ラジオ無線リモコン機器の世界市場展望2017-20276According to Stratistics MRC, the Global Radio Wireless Remote Control Equipment Market is expected to grow at a CAGR of 7.2% during the forecast period. Some of the key factors boosting the market are raising demand for remote control applications. However, administrations at a reasonable cost to increase urgent client base from a neighborhood hampers the market growth of radio wireless remote co …
